Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Valneva slashes 2025 outlook after FDA suspends Ixchiq license, shaking investor confidence
Valneva slashes 2025 outlook after FDA suspends Ixchiq license—discover how the biotech aims to rebuild confidence and cash flow stability.
Can longevity biotech finally go mainstream — or is BioAge’s $250m shelf another warning sign of investor fatigue?
BioAge Labs (NASDAQ: BIOA) files a $250M shelf to fund aging-drug programs. Can disciplined financing revive investor faith in longevity biotech?
Daiichi Sankyo (TSE: 4568) and AstraZeneca (NASDAQ: AZN) surge on Datroway’s historic first-line TNBC survival win
Find out how Datroway’s first-line TNBC survival win could rewrite chemotherapy-first playbooks and accelerate the ADC era in breast cancer—read the full analysis.
Arvinas reports robust phase 1 signals for ARV-102 LRRK2 degrader at MDS 2025, pointing to meaningful target knockdown and brain penetration
Find out how Arvinas’ ARV-102 delivered strong Phase 1 LRRK2 knockdown and brain exposure at MDS 2025—and what it could mean for Parkinson’s trials next.
Why Q/C Technologies’ 6.51m share registration could reshape its stock outlook in 2025
Discover why Q/C Technologies plans to register 6.51M shares for resale, what it signals to investors, and how it could impact QCLS stock.
Ovid Therapeutics (NASDAQ: OVID) surges 28% on $175m private placement: What does it mean for biotech investors?
Ovid Therapeutics (NASDAQ: OVID) jumped 28% after securing $175M via a PIPE deal. Explore its pipeline focus, stock sentiment, and investor outlook.
Rubicon Research IPO: Can General Atlantic’s Rs 1,377cr exit test pharma market appetite?
Rubicon Research’s ₹1,377 crore IPO opens Oct 9. Backed by General Atlantic, can this pharma play sustain growth and deliver listing gains?
DXB rockets on Japan orphan drug win — can Dimerix finally deliver an FSGS breakthrough?
Dimerix (ASX: DXB) secures orphan drug designation in Japan for DMX-200, strengthening its global Phase 3 kidney trial program. Find out what’s next.
AbbVie and Calico secure FDA fast track designation for kidney disease therapy ABBV-CLS-628
AbbVie and Calico’s kidney drug ABBV-CLS-628 wins FDA Fast Track status for ADPKD, reshaping biotech strategy and investor sentiment.
California’s SB 39 exemption protects access to boric acid products as pH-D Feminine Health leads advocacy on women’s wellness
Find out how California’s SB 39 keeps boric acid suppositories accessible as pH-D Feminine Health’s advocacy shapes women’s wellness policy today.